Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0.08% | < 30% | Pass |
| Interest-bearing investments / market cap | 0% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from GLENMARK should be given to charity. Calculate your amount →
Despite a solid 6‑month gain and 50‑day above 200‑day, recent 1–3 month returns are slightly negative and the stock sits moderately below its 52‑week high, pointing to consolidation after prior strength. Volatility is moderate, reflecting a sideways phase rather than a new clear trend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.